NCT01133756 2023-06-22
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
Eisai Inc.
Phase 1/2 Terminated
Eisai Inc.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Eisai Inc.
Eisai Inc.
Eisai Inc.